… OR malignancy) AND (erlotinib OR gefitinib) AND (controlled AND clinical trial). We selected
all randomized studies of erlotinib or gefitinib as treatment of advanced or metastatic stage …

… Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib … randomize
clinical trials (RCTs) of 6,554 patients with NSCLC were pooled in this meta-analysis by random…

… included only randomized controlled trials that compared … randomized controlled trials
have a more stringent and consistent study design, which would ensure consistency of toxicity …

… The breast cancer patients in this study were genotyped using a panel of 14 single-… We
were unable to identify genes related to toxicity in this study. Nevertheless, toxicity was …

… toxicity occurred in 62% and of diarrhea in 57%. For the 250-mg dose, toxicity caused just 1
patient to stop taking gefitinib … In clinical trials of the EGFR inhibitors cetuximab and erlotinib, …

… gefitinib were included in both efficacy and toxicity analyses. OS was defined as the interval
between enrolment in this study … the interval between enrolment in this study and the date of …

… randomised to receive erlotinib (150 mg per day) or gefitinib (250 mg per day) orally until
disease progression or unacceptable toxicity… randomised controlled trial of erlotinib vs gefitinib …

… extracted from seven trials. 15 types of severe toxicity in patients treated with gefitinib or
gefitinib plus … The pooled RRs of all toxicities, diarrhea, and skin toxicity both showed significant …

… Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients
with advanced non–small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to …

… , gefitinib, and radiation in pancreatic and rectal cancers as given in our studies results in
significant toxicity. A recommended phase II dose was not reached in either study given DLTs …